Supratentorial Cancer

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Supratentorial Cancer

MalaCards integrated aliases for Supratentorial Cancer:

Name: Supratentorial Cancer 12 15
Supratentorial Neoplasms 45 74
Brain Neoplasm, Supratentorial 12
Malignant Supratentorial Tumor 12
Cancer, Supratentorial 74


External Ids:

Disease Ontology 12 DOID:1659
MeSH 45 D015173
NCIt 51 C3397 C4964
ICD10 34 C71.0

Summaries for Supratentorial Cancer

Disease Ontology : 12 A brain cancer that is located in the supratentorial region.

MalaCards based summary : Supratentorial Cancer, also known as supratentorial neoplasms, is related to cerebrum cancer and connective tissue benign neoplasm. An important gene associated with Supratentorial Cancer is SYP (Synaptophysin), and among its related pathways/superpathways is Neuroscience. The drugs Morphine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and t cells, and related phenotypes are Increased proliferation and nervous system

Related Diseases for Supratentorial Cancer

Diseases related to Supratentorial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 186)
# Related Disease Score Top Affiliating Genes
1 cerebrum cancer 32.1 GFAP SYP TP53
2 connective tissue benign neoplasm 10.5 ENO2 SYP
3 malignant pheochromocytoma 10.5 ENO2 SYP
4 cranial nerve malignant neoplasm 10.5 ENO2 SYP
5 olfactory neuroblastoma 10.5 ENO2 SYP
6 intraocular retinoblastoma 10.5 ENO2 SYP
7 gastric squamous cell carcinoma 10.5 ENO2 SYP
8 mixed ductal-endocrine carcinoma 10.5 ENO2 SYP
9 carcinoid syndrome 10.5 ENO2 SYP
10 horseshoe kidney 10.5 ENO2 SYP
11 extraskeletal ewing sarcoma 10.5 ENO2 SYP
12 pineoblastoma 10.5 GFAP SYP
13 pilomyxoid astrocytoma 10.5 GFAP SYP
14 binswanger's disease 10.4 GFAP SYP
15 traumatic brain injury 10.4 ENO2 GFAP
16 granular cell tumor 10.4 ENO2 GFAP
17 myxosarcoma 10.4 SYP TP53
18 pulmonary blastoma 10.4 SYP TP53
19 liver angiosarcoma 10.4 ENO2 TP53
20 necrotizing sialometaplasia 10.4 GFAP TP53
21 carotid body cancer 10.4 ENO2 SYP
22 spinal cord astrocytoma 10.4 GFAP TP53
23 gliomatosis cerebri 10.4 GFAP TP53
24 chondroid chordoma 10.4 ENO2 SMARCB1
25 malignant sertoli cell tumor 10.4 ENO2 SYP
26 urinary bladder small cell neuroendocrine carcinoma 10.4 ENO2 SYP
27 auditory system cancer 10.4 ENO2 SYP
28 desmoplastic infantile ganglioglioma 10.4 GFAP SYP
29 sinonasal undifferentiated carcinoma 10.4 ENO2 SYP
30 extraventricular neurocytoma 10.4 GFAP SYP
31 pancreatic somatostatinoma 10.4 ENO2 SYP
32 cutaneous ganglioneuroma 10.4 ENO2 SYP
33 lung combined type small cell carcinoma 10.4 GFAP SYP
34 extrahepatic bile duct adenocarcinoma 10.4 ENO2 SYP
35 small cell carcinoma of the bladder 10.4 ENO2 SYP
36 papillary tumor of the pineal region 10.4 ENO2 SYP
37 epithelial-myoepithelial carcinoma 10.4 SMARCB1 TP53
38 sensory organ benign neoplasm 10.4 ENO2 SYP
39 orbital cancer 10.4 ENO2 SYP
40 intracranial cysts 10.4 ENO2 GFAP
41 middle ear adenoma 10.4 ENO2 SYP
42 primitive neuroectodermal tumor of the cervix uteri 10.4 ENO2 GFAP
43 frontal convexity meningioma 10.4 GFAP TP53
44 pulmonary large cell neuroendocrine carcinoma 10.4 ENO2 SYP
45 large cell neuroendocrine carcinoma 10.4 ENO2 SYP
46 gliofibroma 10.4 GFAP TP53
47 gallbladder small cell carcinoma 10.4 ENO2 SYP
48 cerebellar medulloblastoma 10.4 ENO2 GFAP
49 large cell carcinoma with rhabdoid phenotype 10.4 ENO2 SMARCB1
50 chordoid meningioma 10.4 GFAP SYP

Graphical network of the top 20 diseases related to Supratentorial Cancer:

Diseases related to Supratentorial Cancer

Symptoms & Phenotypes for Supratentorial Cancer

GenomeRNAi Phenotypes related to Supratentorial Cancer according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.8 NF2 SMARCB1 TP53

MGI Mouse Phenotypes related to Supratentorial Cancer:

# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.56 ARTN ENO2 GFAP NF2 RELA SMARCB1
2 vision/eye MP:0005391 9.1 ARTN GFAP NF2 RELA SMARCB1 TP53

Drugs & Therapeutics for Supratentorial Cancer

Drugs for Supratentorial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 191)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Temozolomide Approved, Investigational Phase 4,Phase 2,Phase 1 85622-93-1 5394
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 5311068 68602
Hydrocortisone acetate Approved, Vet_approved Phase 4,Not Applicable 50-03-3
Hydrocortisone Approved, Vet_approved Phase 4,Not Applicable 50-23-7 5754
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 2078-54-8 4943
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
Ibuprofen Approved Phase 4 15687-27-1 3672
Acetaminophen Approved Phase 4 103-90-2 1983
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 83150-76-9 6400441 383414
leucovorin Approved Phase 4,Phase 1 58-05-9 143 6006
Pasireotide Approved Phase 4,Phase 2,Phase 3 396091-73-9 9941444
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 38916-34-6, 51110-01-1 53481605
Cefazolin Approved Phase 4 25953-19-9 33255 656510
Cefdinir Approved Phase 4 91832-40-5 6915944
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
Sulfamethoxazole Approved Phase 4 723-46-6 5329
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 59-30-3 6037
Lactitol Investigational Phase 4 585-88-6, 585-86-4 493591
25 Dexketoprofen trometamol Phase 4
26 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Not Applicable
27 Analgesics, Non-Narcotic Phase 4,Not Applicable
28 Analgesics, Opioid Phase 4,Phase 3,Not Applicable
29 Anti-Inflammatory Agents Phase 4,Phase 1,Not Applicable
30 Analgesics Phase 4,Phase 3,Not Applicable
31 Anti-Inflammatory Agents, Non-Steroidal Phase 4
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Narcotics Phase 4,Phase 3,Not Applicable
34 Antirheumatic Agents Phase 4
35 Alkylating Agents Phase 4,Phase 2,Phase 1
36 Antineoplastic Agents, Alkylating Phase 4,Phase 2,Phase 1
37 Adrenergic Agents Phase 4,Not Applicable
38 Adrenergic Agonists Phase 4,Not Applicable
39 Hydrocortisone hemisuccinate Phase 4,Not Applicable
40 Adrenergic alpha-2 Receptor Agonists Phase 4,Not Applicable
41 Anesthetics Phase 4,Phase 3,Phase 1,Not Applicable
42 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Adrenergic alpha-Agonists Phase 4,Not Applicable
44 Hypnotics and Sedatives Phase 4,Phase 3,Phase 1,Not Applicable
45 Pharmaceutical Solutions Phase 4,Phase 3,Not Applicable
46 Hydrocortisone-17-butyrate Phase 4,Not Applicable
47 Hydrocortisone 17-butyrate 21-propionate Phase 4,Not Applicable
48 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 glucocorticoids Phase 4,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 119)
# Name Status NCT ID Phase Drugs
1 Comparison of Efficacy and Safety of the Postoperative Analgesia Methods Unknown status NCT02929147 Phase 4 Morphine;Dexketoprofen;Placebo
2 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Unknown status NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
3 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Unknown status NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
4 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
5 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
6 Remifentanil Infusion Alone During the Closure Period for Early Emergence Following Craniotomy Completed NCT02593942 Phase 4 Remifentanil;Propofol
7 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
8 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
9 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
10 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
11 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
12 Anaesthesia for Supratentorial Tumor Resection Completed NCT00389883 Phase 3 Comparison of two anesthetics protocol
13 Cabergoline in Nonfunctioning Pituitary Adenomas Completed NCT03271918 Phase 3 Cabergoline
14 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
15 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
16 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
17 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas Recruiting NCT02288962 Phase 3 cabergoline
18 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
19 Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors Completed NCT01689727 Phase 2 Technetium Tc 99m EC20
20 Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. Completed NCT01283542 Phase 2 Pasireotide LAR
21 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Completed NCT00939523 Phase 2 Lapatinib
22 Sandostatin LAR Depot vs. Surgery for Treating Acromegaly Completed NCT00001860 Phase 2 Sandostatin LAR Depot versus transsphenoidal surgery
23 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
24 Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Active, not recruiting NCT02749227 Phase 2 Pasireotide LAR
25 Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas Not yet recruiting NCT03930771 Phase 2 Capecitabine;Temozolomide
26 Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) Terminated NCT00612066 Phase 2 rosiglitazone maleate
27 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
28 Rosiglitazone in Treating Patients With Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
29 Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas Withdrawn NCT01203618 Phase 2 Farletuzumab
30 Temozolomide in Treating Patients With Invasive Pituitary Tumors Withdrawn NCT00601289 Phase 2 temozolomide
31 Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
32 A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma Completed NCT02769533 Phase 1 OTL0038;Benadryl
33 EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors Recruiting NCT03638167 Phase 1
34 A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors or DIPG Recruiting NCT03330197 Phase 1 oral veledimex
35 HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors Recruiting NCT03500991 Phase 1
36 HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors Recruiting NCT02457845 Phase 1
37 Detection of Functioning Pituitary Microadenoma: PET/MRI Versus PET/CT Recruiting NCT03404414 Phase 1 18F-FDG
38 Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide Active, not recruiting NCT00102648 Phase 1 Lonafarnib;Temozolomide
39 Intraoperative Imaging of Pituitary Adenomas by OTL Active, not recruiting NCT02629549 Phase 1 OTL38
40 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
41 Small-dose Dexmedetomidine Effects on Recovery Profiles of Supratentorial Tumors Patients From General Anesthesia Unknown status NCT02007798 Not Applicable dexmedetomidine;normal saline
42 Mannitol Brain Relaxation Effect Unknown status NCT02168075 Not Applicable 0.25g/kgof 20% mannitol;0.5g/kg of 20% mannitol;1.0g/kg of 20% mannitol;1.5g/kg of 20% mannitol
43 Comparison of Stroke Volume Variation-guided Normovolemic and Restrictive Fluid Management During Craniotomy: a Randomized Controlled Trial Unknown status NCT02113358 Not Applicable Intravenous colloid bolus with Voluven
44 Cerebral Blood Circulation in Patients With Posterior Fossa Brain Tumor Unknown status NCT01476670
45 Heart Rate Variability (HRV) in Pituitary Adenoma Unknown status NCT03164148 Not Applicable
46 Comparison of The Effects of Sevoflurane, Desflurane and Total Intravenous Anaesthesia on Pulmonary Function Tests Unknown status NCT02709863 Not Applicable Sevoflurane;Desflurane;Propofol
47 Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Unknown status NCT01775332 Not Applicable
48 Genome-wide Association Study of Pituitary Tumors Unknown status NCT01442220
49 The Predictive Factors of Vision Recovery in Patients With Pituitary Tumor Unknown status NCT01377701
50 The Observational Study of Growth Hormone-secreting Pituitary Tumors Unknown status NCT01368133

Search NIH Clinical Center for Supratentorial Cancer

Cochrane evidence based reviews: supratentorial neoplasms

Genetic Tests for Supratentorial Cancer

Anatomical Context for Supratentorial Cancer

MalaCards organs/tissues related to Supratentorial Cancer:

Pituitary, Brain, T Cells, Pineal, Kidney, Testes, Spinal Cord

Publications for Supratentorial Cancer

Articles related to Supratentorial Cancer:

# Title Authors Year
Intraoperative electrocorticography-guided microsurgical management for patients with onset of supratentorial neoplasms manifesting as epilepsy: a review of 65 cases. ( 24866815 )
Effect of intraoperative glucose fluctuation and postoperative IL-6, TNF-α, CRP levels on the short-term prognosis of patients with intracranial supratentorial neoplasms. ( 25605194 )
Expression of oncoprotein Bcl-2 and bax protein in the infiltration zone and in the parenchyma of primary glia-derived supratentorial neoplasms. ( 10323081 )
Thallium-201-SPECT and 99Tc-HM-PAO SPECT imaging to study functionally cerebral supratentorial neoplasms: the biological basis of the functional imaging interpretation. ( 8803843 )
Supratentorial neoplasms, including the sella and parasellar region. ( 2624769 )
Specificity of computed tomography in the diagnosis of supratentorial neoplasms. Consideration of metastases and meningiomas. ( 745752 )
Carotid angiography in the localisation of supratentorial neoplasms and hamartomata. ( 13624051 )

Variations for Supratentorial Cancer

Expression for Supratentorial Cancer

Search GEO for disease gene expression data for Supratentorial Cancer.

Pathways for Supratentorial Cancer

Pathways related to Supratentorial Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes

GO Terms for Supratentorial Cancer

Biological processes related to Supratentorial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.16 RELA TP53
2 determination of adult lifespan GO:0008340 8.96 RAD54L TP53
3 DNA strand renaturation GO:0000733 8.62 RAD54L TP53

Molecular functions related to Supratentorial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II distal enhancer sequence-specific DNA binding GO:0000980 8.8 RELA SMARCB1 TP53

Sources for Supratentorial Cancer

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
33 HPO
34 ICD10
35 ICD10 via Orphanet
39 LifeMap
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
56 Novoseek
59 OMIM via Orphanet
63 PubMed
71 SNOMED-CT via Orphanet
73 Tocris
75 UMLS via Orphanet
Loading form....